精準基因組檢測市場－全球產業規模、佔有率、趨勢、機會及預測（依技術、產品/服務、應用、最終用途、地區及競爭格局分類，2021-2031年）

全球精準基因組檢測市場預計將從 2025 年的 157.8 億美元成長到 2031 年的 221.7 億美元，複合年成長率達到 5.83%。

該領域專注於分析生物樣本，以識別決定疾病易感性和治療反應的特定基因突變。推動該領域發展的主要因素是慢性病盛行率的上升和先進定序技術成本的下降，這促使人們對精準分子診斷的需求日益成長。為了凸顯這一緊迫性，世界衛生組織（WHO）在2024年預測，到2050年，全球癌症病例數將增加75%以上，這強調了可擴展的診斷工具對於應對這一日益嚴重的健康問題的重要性。

儘管有這些積極跡象，但由於複雜的法規環境和限制性的報銷機制，該行業仍面臨許多障礙。全面的基因組分析缺乏統一的保險覆蓋，往往限制了病患的就醫途徑，並給醫療系統帶來沉重的經濟負擔。因此，建造檢測基礎設施所需的大量資本投入，以及報銷政策的不確定性，都是限制這些診斷解決方案在全球推廣應用的主要阻礙因素。

市場促進因素

液態生物檢體在癌症早期檢測領域的應用正成為市場成長的主要驅動力，它將腫瘤學從被動的組織取樣轉變為主動的、非侵入性的血液監測。這項創新使臨床醫生能夠高靈敏度地檢測循環腫瘤DNA，從而識別微量殘存疾病，並制定個人化的治療方案，且無需承擔手術風險。日益沉重的疾病負擔凸顯了對這種擴充性診斷技術的需求。美國癌症協會預測，光是2025年，美國就將新增超過204.1萬例癌症病例。主要醫療服務提供者正經歷液體活體組織切片技術的顯著普及，Natera公司報告稱，截至2025年2月的會計年度，其收入同比成長56.7%，這主要得益於對其液態生物檢體和基因檢測服務需求的快速成長。

同時，政府加大對人群基因組學研究的投入，為精準醫療的廣泛應用奠定了基礎。國家計畫支持對大型隊列定序，以建立多樣化的基因組生物樣本庫，從而加速藥物研發，並闡明代表性不足人群中複雜疾病的遺傳基礎。這項政府主導的措施顯著增加了可用於研究的臨床級數據量，推動了對高通量定序的需求。例如，2025年2月，美國國立衛生研究院（NIH）宣布其「我們所有人」（All of Us）研究計畫已發布了超過41.4萬名參與者的全基因組序列。這相當於可用資料集增加了約70%，也是推動基因組檢測技術在全球普及的關鍵因素。

市場挑戰

由於報銷限制和保險覆蓋範圍不一致，全球精準基因組檢測市場在全面基因組分析的普及方面面臨許多障礙。儘管定序成本正在下降，但公共和私人支付方之間缺乏標準化的報銷政策，為臨床實驗室和醫療服務提供者帶來了財務上的不確定性。保險公司通常將先進的基因組檢測歸類為實驗性檢測，導致理賠申請經常被拒，並且需要大量的預先核准。這種不確定性使得醫生不願開立必要的診斷檢測處方，因為他們擔心會為患者帶來高額的自付費用，或是擔心診所本身會承擔這些費用。

此外，這些行政負擔擾亂了工作流程，迫使醫療機構將原本用於患者照護的時間用於處理複雜的核准流程。支付模式的不穩定性限制了檢查室對必要檢測基礎設施的投資，從而阻礙了市場擴張。根據美國醫學會 (AMA) 預測，到 2024 年，94% 的醫生將表示，保險公司採用的預先核准通訊協定導致了患者照護的延誤。這項數據凸顯了報銷障礙對營運的影響，直接限制了患者獲得精準醫療的機會，並阻礙了市場的整體成長潛力。

市場趨勢

人工智慧 (AI) 和機器學習 (ML) 的應用正在改變市場格局，它們能夠自動解讀複雜的變異，並促進對大規模多模態資料集的分析。隨著基因測序產生大量數據，AI 演算法能夠快速且準確地識別致病變異，從而消除傳統生物資訊學流程中的瓶頸。這項技術進步正在推動利用 AI 驅動的臨床數據平台的公司商業性成長。例如，Tempus AI 公佈其 2025 年 2 月的年收入為 2.416 億美元（較上年成長 43.2%），這印證了 AI 驅動的基因組分析日益成長的價值。

此外，伴隨診斷（CDx）合作的興起正在加速。隨著藥物研發者越來越依賴精準檢測來指導標靶治療，診斷服務提供者也擴大與生物製藥公司在臨床試驗早期階段合作，以檢驗新藥的綜合基因組分析檢測（而非事後檢驗）。這些策略合作顯著增加了與藥物研發和臨床試驗相關的檢測量，為服務提供者建立了穩定的收入來源。 2025年1月，Guardant Health報告稱，其生物製藥檢測量年增35%，達到約40,500次檢測，這主要得益於合作夥伴對該公司精準腫瘤解決方案日益成長的需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球精準基因組檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依技術分類（次世代定序、聚合酵素鏈鎖反應、微陣列技術、桑格定序、CRISPR/Cas系統等）
  • 依產品/服務分類（耗材（試劑盒/試劑）、設備、服務）
  • 依應用領域（腫瘤學、心血管疾病、神經系統疾病、生殖健康、罕見疾病、其他）
  • 依最終使用者（醫院/診所、診斷檢查室、研究/學術機構、其他）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美精準基因組檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲精準基因組檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區精準基因組檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲精準基因組檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲精準基因組檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球精準基因組檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN NV
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Precision Genomic Testing Market is projected to expand from USD 15.78 Billion in 2025 to USD 22.17 Billion by 2031, achieving a compound annual growth rate of 5.83%. This sector focuses on analyzing biological samples to pinpoint specific genetic modifications that dictate disease susceptibility and therapeutic responses. Growth is largely fueled by the rising prevalence of chronic conditions and the reduced costs of advanced sequencing technologies, which drive the need for precise molecular diagnostics. Highlighting this urgency, the World Health Organization predicted in 2024 that global cancer cases would increase by over 75% by 2050, underscoring the critical need for scalable diagnostic tools to address this escalating health burden.

Despite these positive indicators, the industry confronts significant hurdles stemming from a complicated regulatory environment and restrictive reimbursement frameworks. Variable insurance coverage for thorough genomic profiling frequently limits patient access and imposes financial strains on healthcare systems. Consequently, the substantial capital investment needed to build testing infrastructure, coupled with the unpredictability of reimbursement policies, acts as a primary constraint that threatens to impede the widespread global implementation of these diagnostic solutions.

Market Driver

The shift toward liquid biopsy for early cancer detection acts as a major driver for market growth, transforming oncology from reactive tissue sampling to proactive, non-invasive blood monitoring. This innovation allows clinicians to detect circulating tumor DNA with high sensitivity, identifying minimal residual disease and enabling personalized treatment plans without surgical risks. The necessity for such scalable diagnostics is emphasized by the rising disease burden; the American Cancer Society projected in 2025 that over 2,041,000 new cancer cases would be diagnosed in the United States alone. Leading providers are seeing significant adoption, as evidenced by Natera, Inc., which reported a 56.7% year-over-year revenue increase in its February 2025 financial results, attributed largely to the rapid volume growth of its liquid biopsy and genetic testing offerings.

Simultaneously, rising government investment in population genomics is building the essential infrastructure for widespread precision medicine. National programs are funding the sequencing of large cohorts to establish diverse genomic biobanks, which accelerate drug discovery and elucidate the genetic basis of complex diseases in underrepresented groups. This government-led initiative significantly increases the volume of clinical-grade data available for research, driving demand for high-throughput sequencing. For example, the National Institutes of Health announced in February 2025 that the 'All of Us Research Program' had released whole genome sequences from over 414,000 participants, representing a nearly 70% expansion of the available dataset, thereby acting as a key engine for the global adoption of genomic testing technologies.

Market Challenge

The Global Precision Genomic Testing Market faces substantial obstacles due to reimbursement limitations and inconsistent insurance coverage, which impede the broad utilization of comprehensive genomic profiling. Although sequencing costs have decreased, the absence of standardized reimbursement policies across public and private payers creates financial instability for clinical laboratories and medical providers. Insurers frequently categorize advanced genomic tests as experimental, resulting in regular claim denials or demands for extensive prior authorization. This uncertainty deters physicians from prescribing necessary diagnostics, as they are concerned about imposing heavy out-of-pocket costs on patients or absorbing the expenses within their practice.

Moreover, these administrative burdens disrupt medical practice workflows, requiring significant resources to manage complex approval procedures rather than focusing on patient care. The volatility of payment models hinders market expansion by restricting the capital available for laboratories to invest in essential testing infrastructure. According to the American Medical Association, 94% of physicians reported in 2024 that prior authorization protocols used by insurers caused delays in patient care. This statistic highlights the operational impact of reimbursement barriers, which directly limits patient access to precision medicine and curtails the overall growth potential of the market.

Market Trends

The incorporation of Artificial Intelligence (AI) and Machine Learning (ML) is transforming the market by automating complex variant interpretation and facilitating the analysis of extensive multi-modal datasets. As genomic sequencing yields immense volumes of data, AI algorithms address bottlenecks in traditional bioinformatics pipelines by identifying pathogenic variants with enhanced speed and precision. This technological advancement is fueling commercial growth for companies utilizing AI-driven clinical data platforms; for instance, Tempus AI reported in February 2025 that its Data and Services segment achieved $241.6 million in annual revenue, a 43.2% year-over-year increase that underscores the growing value of AI-enabled genomic insights.

Additionally, the rise of companion diagnostic (CDx) collaborations is accelerating as pharmaceutical developers increasingly depend on precision testing to direct targeted therapies. This trend involves diagnostic providers partnering with biopharmaceutical companies during early-stage clinical trials to validate comprehensive genomic profiling assays alongside new drugs, rather than retrospectively. These strategic alliances significantly boost test volumes linked to drug development and trial enrollment, establishing a consistent revenue stream for providers. In January 2025, Guardant Health reported a 35% year-over-year increase in biopharma test volumes, totaling approximately 40,500 tests, driven by partner demand for its precision oncology solutions.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

Report Scope

In this report, the Global Precision Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Precision Genomic Testing Market, By Technology

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

Precision Genomic Testing Market, By Product & Services

• Consumables (Kits & Reagents)
• Equipment
• Services

Precision Genomic Testing Market, By Application

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

Precision Genomic Testing Market, By End-Use

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others

Precision Genomic Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Precision Genomic Testing Market.

Available Customizations:

Global Precision Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Precision Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
  • 5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
  • 5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
  • 5.2.4. By End-Use (Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Precision Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product & Services
  • 6.2.3. By Application
  • 6.2.4. By End-Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-Use
  • 6.3.2. Canada Precision Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-Use
  • 6.3.3. Mexico Precision Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-Use

7. Europe Precision Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product & Services
  • 7.2.3. By Application
  • 7.2.4. By End-Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Precision Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-Use
  • 7.3.2. France Precision Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-Use
  • 7.3.3. United Kingdom Precision Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-Use
  • 7.3.4. Italy Precision Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-Use
  • 7.3.5. Spain Precision Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-Use

8. Asia Pacific Precision Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product & Services
  • 8.2.3. By Application
  • 8.2.4. By End-Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-Use
  • 8.3.2. India Precision Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-Use
  • 8.3.3. Japan Precision Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-Use
  • 8.3.4. South Korea Precision Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-Use
  • 8.3.5. Australia Precision Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-Use

9. Middle East & Africa Precision Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product & Services
  • 9.2.3. By Application
  • 9.2.4. By End-Use
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Precision Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-Use
  • 9.3.2. UAE Precision Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-Use
  • 9.3.3. South Africa Precision Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-Use

10. South America Precision Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product & Services
  • 10.2.3. By Application
  • 10.2.4. By End-Use
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Precision Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-Use
  • 10.3.2. Colombia Precision Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-Use
  • 10.3.3. Argentina Precision Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Genomic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Revvity, Inc.
• 15.4. Maravai LifeSciences
• 15.5. GenScript Biotech
• 15.6. QIAGEN N.V.
• 15.7. PacBio Biosciences Inc.
• 15.8. Oxford Nanopore Technologies plc.
• 15.9. Illumina, Inc.
• 15.10. 10x Genomics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer